Aimed Bio Inc

Aimed Bio Inc maintains a strong liquidity position, with a current ratio of 31.43, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to KRW 106,407,975,730, which is a substantial portion of its total assets of KRW 198,968,698,740. The liquidity_fpt metric further supports this, showing a high level of financial flexibility. The company's debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing.

In terms of profitability, Aimed Bio Inc reports a return on equity (ROE) of 2.61% and a return on assets (ROA) of 2.52%. These figures are below the industry median for ROE and ROA, indicating that the company is generating returns at a lower rate compared to its peers. The net income of KRW 5,022,565,520 and operating income of KRW 20,769,485,300 suggest a profitable operation, but the gross profit margin of 96.78% (calculated from revenue and gross profit) indicates that the company is maintaining strong margins in its core operations.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This concentration may expose the company to higher operational and market risks if the segment or region experiences a downturn. The lack of segmental or geographic diversification is a notable risk factor, especially in a volatile industry like biotechnology.

Looking ahead, Aimed Bio Inc is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the next fiscal year. The company's free cash flow of KRW 6,037,470,260 and operating cash flow of KRW 17,860,180,440 support its ability to fund operations and invest in growth opportunities. The capital expenditure of KRW -362,628,880 (negative, indicating a reduction in capital spending) suggests a focus on optimizing existing assets rather than expanding new ones.

The risk assessment for Aimed Bio Inc indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and high cash reserves further support this assessment. However, the potential for dilution remains low, with no significant dilution sources identified in recent filings or disclosures. The company's conservative capital structure and strong liquidity position reduce the likelihood of near-term dilution pressure.

Recent events and filings for Aimed Bio Inc have not indicated any material changes in the company's financial or operational status. The company's financial statements and disclosures remain consistent with its historical performance, and there are no notable regulatory or legal issues reported in the latest filings. The absence of significant events or changes in the company's operations supports the stability of its current financial position.

Aimed Bio Inc (0009K0.KQ) has undergone a significant update to its corporate profile, with its economic sector now formally classified as Healthcare and its primary activity identified as Pharmaceuticals & Medical Research. This medium-severity change establishes the company’s operational context, moving from an undefined state to a clear categorization within the healthcare industry. Concurrently, the company’s risk assessment metrics have been initialized, with both dilution risk and liquidity risk now rated as low. These new fields, previously null, indicate that current data suggests minimal immediate threat regarding share dilution or cash flow constraints, classified as low severity based on established thresholds. The significance of these updates lies in the establishment of a baseline for financial and operational analysis. By defining its sector and activity, Aimed Bio Inc provides clarity on its business model, while the low-risk ratings offer initial reassurance regarding capital structure stability and marketability. Despite these profile enhancements, the company currently lacks external validation from analysts or index memberships, and no top holders or officers are recorded in the available data. This absence of broader market engagement suggests that while the internal risk and classification metrics are stable, the company remains in an early stage of public market visibility. [doc:0009k0.kq-ha-financials]